Endosense, a medical technology company focused on catheter ablation to treat cardiac arrhythmias, has received $36 million in series B financing.
Edmond de Rothschild Investment Partners led the round, with additional participation from Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.
The Geneva-based company said the financing will primarily be used to fund the European commercialization and U.S. premarket approval clinical study of the company’s force-sensing ablation catheter, the TactiCath, which was granted the CE Mark in May.
As part of the series B activity, Endosense said it has made several board appointments to reflect its new shareholder mix. Edmond de Rothschild’s Partner Olivier Litzka, Gimv’s Executive Vice President of Life Sciences Patrick van Beneden and VI Partner’s Diego Braguglia have become directors.